Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).
M Angelyn BethelRishi A PatelVivian P ThompsonPeter MerrillShelby D ReedYanhong LiSara AhmadiBrian G KatonaStephanie M GustavsonPeter OhmanNayyar IqbalRobert F GagelAdrian F HernandezJohn B BuseRury R Holmannull nullPublished in: Diabetes care (2019)
During a median 3.2 years' follow-up, no change in serum calcitonin was seen with exenatide therapy. The three confirmed cases of MTC all occurred in participants with markedly elevated baseline calcitonin levels, measured prior to trial medication administration. Regular calcitonin monitoring identified no additional cases of MTC, suggesting no benefit of routine calcitonin monitoring during exenatide treatment.